TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568): Revisiting Valuation After ENHERTU’s Landmark First-Line FDA Approval
Daiichi Sankyo Company (TSE:4568) just picked up a major US win, with the FDA approving ENHERTU plus pertuzumab as first line therapy for unresectable or metastatic HER2 positive breast cancer, reshaping expectations around its oncology growth story.
See our latest analysis for Daiichi Sankyo Company.
The ENHERTU milestone lands after a mixed run in the market, with the latest share price at ¥3,462 and a year to date share price return of about negative 19 percent, even as the five year total...